Antiretroviral therapy: Is it the right time for new strategies?

被引：2

作者：

Abrescia, N ^{[1
]}

D'Abbraccio, M ^{[1
]}

Busto, A ^{[1
]}

Maddaloni, A ^{[1
]}

Figoni, M ^{[1
]}

De Marco, M ^{[1
]}

机构：

[1] AO Cotugno Reg Hosp Infect Dis, Div Infect Dis 4, I-80131 Naples, Italy

来源：

LETTERS IN DRUG DESIGN & DISCOVERY | 2005年 / 2卷 / 06期

关键词：

HIV; AIDS; HAART; HIV treatment new strategies;

D O I：

10.2174/1570180054771536

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The current antiretroviral regimens in the long run, can lead to poor adherence to treatment, to emergence of resistant viral strains and different adverse effects limiting benefits of HAART. A variety of novel treatment strategies have been proposed to help the long-term management of HAART. The principal innovative therapeutic strategies under investigation will be discussed: treatment simplification, once daily regimens, structured or response guided treatment interruptions and proactive antiretroviral switching.

引用

页码：470 / 474

页数：5

共 36 条

[21] Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure [J].

Miller, V ;

Sabin, C ;

Hertogs, K ;

Bloor, S ;

Martinez-Picado, J ;

D'Aquila, R ;

Larder, B ;

Lutz, T ;

Gute, P ;

Weidmann, E ;

Rabenau, H ;

Phillips, A ;

Staszewski, S .

AIDS, 2000, 14 (18) :2857-2867

[22] Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial) [J].

Molina, JM ;

Peytavin, G ;

Perusat, S ;

Lascoux-Combes, C ;

Sereni, D ;

Rozenbaum, W ;

Chene, G .

HIV MEDICINE, 2004, 5 (02) :99-104

[23] Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients [J].

Monforte, AD ;

Lepri, AC ;

Rezza, G ;

Pezzotti, P ;

Antinori, A ;

Phillips, AN ;

Angarano, G ;

Colangeli, V ;

De Luca, A ;

Ippolito, G ;

Caggese, L ;

Soscia, F ;

Filice, G ;

Gritti, F ;

Narciso, P ;

Tirelli, U ;

Moroni, M .

AIDS, 2000, 14 (05) :499-507

[24] A risk-benefit assessment of HIV protease inhibitors [J].

Moyle, GJ ;

Gazzard, BG .

DRUG SAFETY, 1999, 20 (04) :299-321

[25]

Moyle Graeme J, 2004, AIDS Read, V14, P380

[26]

Negredo E, 2004, ANTIVIR THER, V9, P889

[27] Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine [J].

Negredo, E ;

Ribalta, J ;

Paredes, R ;

Ferré, R ;

Sirera, G ;

Ruiz, L ;

Salazar, J ;

Reiss, P ;

Masana, L ;

Clotet, B .

AIDS, 2002, 16 (10) :1383-1389

[28] Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression [J].

Negredo, E ;

Cruz, L ;

Paredes, R ;

Ruiz, L ;

Fumaz, CR ;

Bonjoch, A ;

Gel, S ;

Tuldrà, A ;

Balagué, M ;

Johnston, S ;

Arnó, A ;

Jou, A ;

Tural, C ;

Sirera, G ;

Romeu, J ;

Clotet, B .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (04) :504-510

[29] Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort [J].

O'Brien, ME ;

Clark, RA ;

Besch, CL ;

Myers, L ;

Kissinger, P .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 (04) :407-414

[30] A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection [J].

Opravil, M ;

Hirschel, B ;

Lazzarin, A ;

Furrer, H ;

Chave, JP ;

Yerly, S ;

Bisset, LR ;

Fischer, M ;

Vernazza, P ;

Bernasconi, E ;

Battegay, M ;

Ledergerber, B ;

Günthard, H ;

Howe, C ;

Weber, R ;

Perrin, L .

JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (09) :1251-1260

← 1 2 3 4 →